Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS traded down $0.50 during midday trading on Tuesday, hitting $15.52. 452,163 shares of the stock traded hands, compared to its average volume of 2,828,111. The firm has a 50-day moving average of $15.64 and a two-hundred day moving average of $12.66. The firm has a market capitalization of $1.31 billion, a P/E ratio of -31.10 and a beta of 0.94. Corvus Pharmaceuticals has a one year low of $3.16 and a one year high of $26.95.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CRVS shares. HC Wainwright increased their price target on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. The Goldman Sachs Group initiated coverage on Corvus Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. Jefferies Financial Group raised their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Orbimed Advisors LLC raised its holdings in Corvus Pharmaceuticals by 3.2% in the 2nd quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock worth $28,660,000 after purchasing an additional 221,352 shares during the period. Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 5.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock worth $25,588,000 after purchasing an additional 191,216 shares during the period. State Street Corp increased its stake in Corvus Pharmaceuticals by 177.1% in the 4th quarter. State Street Corp now owns 2,788,223 shares of the company’s stock worth $21,469,000 after buying an additional 1,781,904 shares in the last quarter. MPM Bioimpact LLC bought a new stake in Corvus Pharmaceuticals during the fourth quarter valued at about $21,126,000. Finally, Geode Capital Management LLC raised its holdings in Corvus Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,473,026 shares of the company’s stock valued at $11,345,000 after acquiring an additional 16,498 shares during the period. 46.64% of the stock is owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.